Brain Tumours

First page Previous page 915 Next page Last page

Studiendesign Aims of the Trial

Author Division Olaf Witt SIOP LGG 201X

PAge68 1/25/2016 | a

• Reduction of neurotoxicity • Introduce combined primary endpoint : + PFS (MRI)

+ neurological function (VABS II) + visual function (VA, LogMAR) • Biology: biomarker for prediction of natural course of LGG, prediction response to chemotherapy/targeted therapy • Introduction of targeted compounds asap after promising phase II data

Made with